Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elgene Lim

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|February 11, 2024
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trialCarlo Palmieri, Hannah Linden, Stephen N Birrell, et al.
Nature Communications|June 15, 2018
A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexesEvangelia K Papachristou, Kamal Kishore, Andrew N Holding, et al.
Drug Safety|August 8, 2023
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary PanelJoanne Wing Yan Chiu, Soo Chin Lee, James Chung-Man Ho, et al.
Cell Reports|March 9, 2017
Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast CancerKoen M A Dreijerink, Anna C Groner, Erica S M Vos, et al.
NPJ Breast Cancer|September 1, 2021
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibitionDiar Aziz, Neil Portman, Kristine J Fernandez, et al.
Elife|March 13, 2018
Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cellsYubao Wang, Young-Mi Li, Lukas Baitsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE DataFrederick M Howard, Peter A Fasching, Cesar A Santa-Maria, et al.
Clinical Breast Cancer|September 23, 2022
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast CancerVanessa Wong, Richard de Boer, Sally Baron-Hay, et al.
Elife|May 22, 2014
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cellsYubao Wang, Young-Mi Lee, Lukas Baitsch, et al.
Cancers|May 28, 2022
Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to CisplatinJean Berthelet, Momeneh Foroutan, Dharmesh D Bhuva, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|February 11, 2024
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trialCarlo Palmieri, Hannah Linden, Stephen N Birrell, et al.
Nature Communications|June 15, 2018
A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexesEvangelia K Papachristou, Kamal Kishore, Andrew N Holding, et al.
Drug Safety|August 8, 2023
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary PanelJoanne Wing Yan Chiu, Soo Chin Lee, James Chung-Man Ho, et al.
Cell Reports|March 9, 2017
Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast CancerKoen M A Dreijerink, Anna C Groner, Erica S M Vos, et al.
NPJ Breast Cancer|September 1, 2021
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibitionDiar Aziz, Neil Portman, Kristine J Fernandez, et al.
Elife|March 13, 2018
Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cellsYubao Wang, Young-Mi Li, Lukas Baitsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE DataFrederick M Howard, Peter A Fasching, Cesar A Santa-Maria, et al.
Clinical Breast Cancer|September 23, 2022
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast CancerVanessa Wong, Richard de Boer, Sally Baron-Hay, et al.
Elife|May 22, 2014
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cellsYubao Wang, Young-Mi Lee, Lukas Baitsch, et al.
Cancers|May 28, 2022
Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to CisplatinJean Berthelet, Momeneh Foroutan, Dharmesh D Bhuva, et al.
Pageof 13